Tizanidine Tablet
Product Images NDC 67296-2263

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-2263). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Tizanidine Tablets USP 2 mg oral tablets. The label includes a warning that these tablets are not interchangeable with Tizanidine capsules. The package contains 150 tablets. Manufactured by Dr. Reddy's Laboratories Limited, India, and labeled for Northstar Rx LLC, Memphis, TN. The label displays storage instructions, a barcode, and the NorthStar logo.*

FDA Label Image

Container2 (Container2)

Label for Tizanidine Tablets, USP 4 mg, oral tablets, containing 150 tablets per container. The label notes these tablets are not interchangeable with Tizanidine Capsules and are Rx only. Manufactured by Dr. Reddy's Laboratories Limited, India, for Northstar Rx LLC, Memphis, TN. Storage instructions and dosage details are included along with barcode and product codes.*

FDA Label Image

Fig1 (Fig1)

A pharmacokinetic curve chart showing plasma Tizanidine concentration (ng/mL) versus time in hours after dosing. The chart compares 2 x 4 mg Tizanidine tablets and capsules taken with and without food, illustrating differences in drug concentration over 24 hours post-dose.*

FDA Label Image

Fig2 (Fig2)

Line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg and 8 mg tizanidine doses compared to placebo. The x-axis represents hours post-dose, and the y-axis shows improvement in Ashworth Score, with error bars indicating variability. 16 mg tizanidine shows the greatest improvement followed by 8 mg, with placebo showing minimal change.*

FDA Label Image

Fig3 (Fig3)

A line graph showing improvement in Ashworth Score over time for tizanidine (mean dose 28.8 mg) versus placebo. Data points with error bars are presented at three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The tizanidine group shows greater improvement compared to placebo across all time points.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride, showing the molecular connectivity of its atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.